IMC-A12 safety and optimal dose explored in advanced cancer patients unresponsive to standard treatments

Many cancers become refractory to standard treatments, leaving patients with limited or no therapeutic options. The insulin-like growth factor 1 receptor (IGF-1R) pathway is often implicated in tumor growth, survival, and resistance to therapy, making it a promising target for novel interventions. Current therapies may fail due to acquired resistance or inherent tumor aggressiveness, necessitating new agents that can overcome these challenges. IMC-A12, an anti-IGF-1R monoclonal antibody, aims to address this unmet need by targeting this critical pathway in advanced malignancies.

This Phase 1 study enrolled participants with advanced tumors refractory to standard therapies or lacking treatment options. The primary objective was to assess the safety profile of IMC-A12 and identify its maximum tolerated dose (MTD). This involved a dose-escalation design, where increasing doses of IMC-A12 were administered to cohorts of patients. Secondary objectives likely included preliminary pharmacokinetic assessments, though not explicitly stated. The study aimed to establish a safe and effective dosing regimen for future clinical development.